
[Cancer Research 52, 6031-6035, November 1, 1992]
© 1992 American Association for Cancer Research
Gastrin Stimulates Ca2+ Mobilization and Clonal Growth in Small Cell Lung Cancer Cells
Tariq Sethi and
Enrique Rozengurt1
Imperial Cancer Research Fund, P. O. Box 123, 44 Lincoln's Inn Fields, London WC2A 3PX, England
Gastrin has been postulated to be a physiological growth factor, but compelling in vitro evidence of this has been difficult to obtain. In the present study we investigated whether small cell lung carcinoma cell lines could provide a useful model system to study the effects of gastrin on signal transduction and cell proliferation in vitro. We found that the addition of gastrin to small cell lung cancer cells loaded with the fluorescent Ca2+ indicator fura 2-tetraacetoxymethylester causes a rapid and transient increase in the intracellular concentration of Ca2+ ([Ca2+]i) followed by homologous desensitization. The [Ca2+ ]i response was especially prominent in the small cell lung carcinoma cell line H510. In this cell line, gastrin I, gastrin II, cholecystokinin residues 2633 (CCK-8), and unsulfated CCK-8 increased [Ca2+]i in a concentration-dependent fashion with half-maximum effects at 7, 2.5, 3, and 5 nM, respectively.
The Ca2+-mobilizing effects of gastrin and CCK-8 were prevented by proglumide, benzotript, and the specific gastrin/CCKB receptor antagonist L365260. Gastrin stimulated the clonal growth of H510 cells in semisolid (agarose-containing) medium, increasing both the number and the size of the colonies. Gastrin and CCK agonists were equally effective in promoting clonal growth. The broad-spectrum neuropeptide antagonists [D-Arg1, D-Phe5, D-Trp7,9,Leu11] substance P and [Arg6,D-Trp7,9,MePhe8] substance P (611) markedly inhibited gastrin-stimulated Ca2+ mobilization and clonal growth. These results show that gastrin acts as a direct growth factor through gastrin/CCKB receptors and demonstrate, for the first time, that these peptides can stimulate the proliferation of cells outside the gastrointestinal tract.
1 To whom requests for reprints should be addressed.
Received 4/30/92.
Accepted 8/24/92.
This article has been cited by other articles:

|
 |

|
 |
 
M. Dufresne, C. Seva, and D. Fourmy
Cholecystokinin and gastrin receptors.
Physiol Rev,
July 1, 2006;
86(3):
805 - 847.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-J. Cheng, K. G. Harikumar, E. L. Holicky, and L. J. Miller
Heterodimerization of Type A and B Cholecystokinin Receptors Enhance Signaling and Promote Cell Growth
J. Biol. Chem.,
December 26, 2003;
278(52):
52972 - 52979.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Clive, D. J. Webb, A. MacLellan, A. Young, B. Byrne, L. Robson, J. F. Smyth, and D. I. Jodrell
Forearm Blood Flow and Local Responses to Peptide Vasodilators: A Novel Pharmacodynamic Measure in the Phase I Trial of Antagonist G, a Neuropeptide Growth Factor Antagonist
Clin. Cancer Res.,
October 1, 2001;
7(10):
3071 - 3078.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. REHFELD
The New Biology of Gastrointestinal Hormones
Physiol Rev,
October 1, 1998;
78(4):
1087 - 1108.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1992 by the American Association for Cancer Research.